Related Experiment Videos
Lipid microparticles as sustained release system for a GnRH antagonist (Antide)
M D Del Curto1, D Chicco, M D'Antonio
1Industria Farmaceutica Serono, Drug Delivery Systems, BioIndustry Park, via Ribes 5, I-10010 Colleretto Giacosa, Turin, Italy. mariadorly.delcurto@serono.com
Summary
Lipid microparticles (LMs) offer sustained release of gonadotropin-releasing hormone (GnRH) antagonist (Antide) for at least 30 days. Formulation and processing methods influence drug release and pharmacodynamic effects.
Area of Science:
- Pharmacology
- Materials Science
- Biotechnology
Background:
- Sustained drug delivery systems are crucial for improving therapeutic efficacy and patient compliance.
- Gonadotropin-releasing hormone (GnRH) antagonists require effective delivery systems for prolonged action.
Purpose of the Study:
- To develop and evaluate lipid microparticles (LMs) for sustained release of a GnRH antagonist (Antide).
- To investigate the impact of lipid matrix and incorporation method on Antide release kinetics and in vivo performance.
Main Methods:
- Preparation of Antide-loaded LMs using cryogenic micronization with glyceryl monobehenate or glyceryl monostearate.
- Incorporation methods included co-melting and solvent evaporation.
- Characterization involved RP-HPLC, laser diffractometry, SEM, in vitro release studies, and in vivo pharmacodynamic assessment in rats.
Main Results:
- Antide-LMs exhibited a mean diameter of approximately 30 µm.
- Drug release varied based on lipid matrix and incorporation method.
- Co-melting of Antide-LMs with Compritol E ATO demonstrated detectable plasma levels for over 30 days in rats.
- In vitro release correlated well with in vivo pharmacokinetics, showing sustained testosterone suppression.
Conclusions:
- Lipid microparticles can effectively sustain the release of Antide for at least one month.
- Formulation parameters, including lipid composition and processing conditions, significantly influence drug release profiles and therapeutic outcomes.